New drug ALK-N001 targets advanced solid tumors in early trial
NCT ID NCT07509684
First seen Apr 07, 2026 · Last updated May 02, 2026 · Updated 5 times
Summary
This study tests an injectable drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing, and to check its safety. The trial is in early phases (Ib and II) and is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.